This year, the World Medical Innovation Forum will explore the promise of new gene and cell therapies, the challenges to their development and investment and market dynamics. The forum features more than 200 CEOs, industry, investment, and government senior leaders from across the Gene and Cell Therapy (GCT) ecosystem.

On Tuesday, May 3, Colin Hill, will take part in a panel discussion titled “Control or Mitigation of the Effects of Chronic Neuroinflammation”. He will be joined by Spyros Papapetropoulos, MD, PhD, CMO, Vigil Neuroscience; Richard Ransohoff, MD, CMO, Abata Therapeutics and Venture Partner, Third Rock Ventures; Beth Stevens, PhD, HHMI Investigator, F.M. Kirby Neurobiology Research Program, Boston Children’s Hospital & Associate Professor of Neurology, HMS; Rudolph Tanzi, PhD, Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH and Joseph P. and Rose F. Kennedy Professor of Neurology, HMS. The session will be moderated by Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean and Professor, Neurology and Neuroscience, HMS.

Panel session | 4:35 PM – 5:15 PM ET | Control or Mitigation of the Effects of Chronic Neuroinflammation.

More information: https://worldmedicalinnovation.org/events/control-or-mitigation-of-the-effects-of-chronic-neuroinflammation/